Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




FDA Panel Says No to Canakinumab for Gout AttacksFDA Panel Says No to Canakinumab for Gout Attacks
Link ID 36461
Title FDA Panel Says No to Canakinumab for Gout AttacksFDA Panel Says No to Canakinumab for Gout Attacks
Url http://www.medscape.com/viewarticle/745076?src=rsshttp://www.medscape.com/viewarticle/745076?src=rss
Description For the FDA Arthritis Advisory Committee, the injectable biologic canakinumab may be promising for a niche group of patients, but fears about long-term safety kept them from voting for its approval. br / iMedscape Medical News/i
Category Articles > Rheumatology
Keywords
Date Jun 22, 2011
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Rheumatology
1. Methotrexate Pharmacokinetics Point Toward Possible Alternative Dosing
  In patients with rheumatoid arthritis (RA), it can take 6 months for oral methotrexate (MTX) to reach steady-state blood levels, according to a study by researchers in New Zealand published in the November issue of Arthritis & Rheumatism. The authors also found that in patients who had discontinued MTX, elimination of the drug from red blood cells was also slow. Reuters Health Information
Category:   Articles > Rheumatology


2. Developments in the Scientific Understanding of Osteoarthritis
  Arthritis treatment in the past decade is starting to focus on the whole joint instead of just cartilage. Arthritis Research & Therapy
Category:   Articles > Rheumatology


3. Perspective on the Risks of Infection and Malignancy With Rheumatoid Arthritis Therapy
  Anti-TNF agents have been associated with increased risks of malignancies and infections in RA. What do we know already about these risks and what is the future direction for safe RA treatment?
Future Rheumatology
Category:   Articles > Rheumatology


4. Relevance of Osteoproliferation as an Outcome Parameter in Ankylosing Spondylitis
  This viewpoint explores the relevance of osteoproliferation amongst other outcome parameters in akylosing spondylitis for monitoring the structural damage of the disease.
Nature Clinical Practice Rheumatology
Category:   Articles > Rheumatology


5. Rituximab Efficacy in Rheumatoid Arthritis Depends on B Cell Depletion
  The clinical efficacy of rituximab in rheumatoid arthritis (RA) depends on the degree of B cell depletion rather than the dose of rituximab, researchers from the UK report in the December 28th Arthritis & Rheumatism online. Reuters Health Information
Category:   Articles > Rheumatology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS